HMB-TZD

HMB-TZD (5-(4-hydroxy-2,3,5-trimethylbenzylidene) thiazolidin-2,4-dione) is a small molecule benzylidenethiazole analog that acts as a potent inhibitor of arachidonate 5-lipoxygenase (5-LOX). Developed by the Korea Research Institute of Bioscience and Biotechnology (KRIBB), it has been investigated for its anti-atherogenic properties. In preclinical models, HMB-TZD significantly reduces the production of leukotriene B4 (LTB4), a proinflammatory mediator, which leads to decreased monocyte adhesion, migration, and macrophage accumulation in atherosclerotic lesions. Unlike traditional thiazolidinediones, HMB-TZD does not function as a PPARγ agonist and does not alter plasma glucose or lipid profiles, suggesting its effects are primarily mediated through the 5-LOX pathway and the subsequent downregulation of adhesion molecules like VCAM-1 and chemoattractants like MCP-1.

Other names

5-(4-hydroxy-2,3,5-trimethylbenzylidene) thiazolidin-2,4-dione5-(4-hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione